Tonix Pharmaceuticals is enrolling participants in a Phase 3 trial for fibromyalgia.
For more information, please visit www.thereliefstudy.com or www.clinicaltrials.gov (NCT04172831).
- Home
- Investors
- News / Press Releases
- Press Releases
Press Releases
Tonix Pharmaceuticals to Present FDA Breakthrough Therapy-Designated PTSD Program at the MicroCap Conference in New York
Tonix Pharmaceuticals Achieves 50 Percent Enrollment in Phase 3 Trial of FDA-Designated Breakthrough Therapy Tonmya® (Cyclobenzaprine HCl Sublingual Tablets) for the Treatment of PTSD
Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL
Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update
Tonix Pharmaceuticals to Present at the 30th Annual ROTH Conference
Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors
Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City
Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale
